The Multiple Myeloma Daily
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Related Articles
Myeloma Paper of the Day, May 20th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, May 20th, suggested by Robert Orlowski / Alex H. Chang, Bai-tao Dou, cancer, Dan Chen, Fang-yi Fan, Hao Yao, Jiao…
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial – PubMed
Relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD) represents a challenging condition, with limited treatment options and poor prognosis. We conducted a phase 1 clinical…
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström’s Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors – PubMed
Over the last decade, covalent Bruton tyrosine kinase (BTK) inhibitors have become a standard option for treating patients with symptomatic Waldenström Macroglobulinemia (WM) in the…
Global, regional, and national burden of multiple myeloma from 1990 to 2021 and projections for 2040: a systematic analysis for the global burden of disease 2021 study – PubMed
Driven by population aging and advancements in diagnostic capabilities, the global burden of multiple myeloma continues to rise. Targeted prevention and treatment strategies, particularly for…
Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma – PubMed
Multiple myeloma (MM) is characterized by genetic abnormalities in plasma cells, requiring precise genomic characterization for effective risk stratification and treatment. This study presents the…
Extramedullary Myeloma is Genomically Complex and Characterized by Near-Universal MAPK Pathway Alterations – PubMed
Extramedullary disease (EMD) is associated with an inferior prognosis and lower response rates to conventional multiple myeloma (MM)-directed therapies compared to MM without EMD. A…
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells – PubMed
Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are in urgent need of additional…
High-Deductible Health Plans and Out-of-Pocket Health Care Costs Among Younger Patients With Multiple Myeloma – PubMed
Compared with standard plan enrollees, OOP costs were higher for HDHP enrollees in the year after diagnosis, but HDHP enrollment was not associated with delays…
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium – PubMed
Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily…